Jeffrey D Hulmes

US Patent:

6683046, Jan 27, 2004

Filed:

Jun 2, 1995

Appl. No.:

08/459151

Inventors:

Maurice Kent Gately - Montville NJ
Ulrich Andreas Gubler - Glen Ridge NJ
Jeffrey David Hulmes - Ringwood NJ
Frank John Podlaski - New City NY
Alvin Seth Stern - Passaic Park NJ
Richard Anthony Chizzonite - South Kent CT
Yu-Ching Eugene Pan - Pine Brook NJ

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

C07K 1400

US Classification:

514 2, 530351, 530350, 530399, 424 851, 424 852

Abstract:

The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md. ). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.

US Patent:

8110187, Feb 7, 2012

Filed:

Oct 8, 2002

Appl. No.:

10/267565

Inventors:

Maurice Kent Gately - Montville NJ, US
Ulrich Andreas Gubler - Glen Ridge NJ, US
Jeffrey David Hulmes - Ringwood NJ, US
Frank John Podlaski - New City NY, US
Alvin Seth Stern - Passaic Park NJ, US
Richard Anthony Chizzonite - South Kent CT, US
Yu-Ching Eugene Pan - Pine Brook NJ, US

Assignee:

Hoffman-La Roche Inc. - Nutley NJ

International Classification:

A61K 39/395
C07K 16/24

US Classification:

4241301, 4241581, 5303881, 53038823

Abstract:

The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md. ). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.

US Patent:

57805970, Jul 14, 1998

Filed:

Jun 2, 1995

Appl. No.:

8/460061

Inventors:

Maurice Kent Gately - Montville NJ
Ulrich Andreas Gubler - Glen Ridge NJ
Jeffrey David Hulmes - Ringwood NJ
Frank John Podlaski - New City NY
Alvin Seth Stern - Passaic Park NJ
Richard Anthony Chizzonite - South Kent CT
Yu-Ching Eugene Pan - Pine Brook NJ

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

C07K 1624
C12P 2108

US Classification:

53038823

Abstract:

The present invention relates to antibodies which bind to a novel cytotoxic lymphocyte maturation factor. When bound to the cytotoxic lymphocyte maturation factor, the antibodies can neutralize bioactivity of the factor.